

T3:PO.70

### To report on the weight loss achieved in 8 weeks by 1810 female patients with BMI 25-29.9 on the LighterLife Lite LCD weight-loss programme in 2009; a retrospective study

**Hallam CL**, Mullins G, du Plessis J, Cox JSA and Hewlett B  
*LighterLife, Cavendish House, Harlow Business Park, Parkway, Harlow, Essex, UK*

**Introduction:** LighterLife Lite is a commercial weight-management programme for patients with BMI 25–29.9. Weight loss is achieved with a low-calorie diet (LCD), comprising fortified, formula-food replacements and a calorie/carbohydrate-restricted meal, providing a daily intake of 801–1200 kcal, alongside behavioural modification specifically designed for weight management using transactional analysis and cognitive behavioural therapy techniques (TCBT). Following weight loss, there is an ongoing weight-maintenance programme to implement and sustain healthy lifestyle changes, and thus reduce the risk of co-morbidities.

**Aim:** To determine mean weight loss and BMI reduction for female patients following 8 weeks on the LighterLife Lite weight-loss programme in 2009.

**Method:** Following screening for suitability, patients started LCD and were weighed weekly by their LighterLife weight-management counsellors. Data was available for 1810 women with BMI 25–29.9 who participated in the LighterLife Lite LCD for 8 weeks from February–August 2009.

**Results:** After 8 weeks on the LighterLife Lite LCD, mean weight loss was 7.1 kg (1st 2lb), mean BMI reduction was 2.7 and mean percentage weight loss 9.4%.

Mean start weight	75.1 kg (11st 12lb)
Mean start BMI	27.7
Mean weight loss at 8 weeks	7.1 kg (1st 2lb)
Mean % weight loss	9.4%
Mean end BMI	25.0
Mean BMI reduction	2.7

**Conclusion:** Patients completing 8 weeks on the LighterLife Lite LCD programme achieved a mean loss of 7.1kg (1st 2lb; average 2lb per week), which is a mean BMI reduction of 2.7 and a reduction of 9.4% of body weight. This may improve health outcomes by reducing the risk of weight-related co-morbidities.

T3:PO.71

### To report on the weight loss achieved in 8 weeks by 950 obese male patients on the LighterLife Total for Men VLCD weight-loss programme in 2009; a retrospective study

**Hallam CL**, Mullins G, du Plessis J, Cox JSA and Hewlett B  
*LighterLife, Cavendish House, Harlow Business Park, Parkway, Harlow, Essex, UK*

**Introduction:** LighterLife Total for Men is a commercial weight-management programme for men with BMI $\geq$ 30. Weight loss is achieved with a nutritionally complete, very-low-calorie diet (VLCD) providing a minimum 50 g protein/carbohydrate, alongside behavioural modification specifically designed for men using transactional analysis and cognitive behavioural therapy techniques (TCBT). Following weight loss, there is an ongoing weight-maintenance programme to help patients implement and sustain healthy lifestyle changes, and thus reduce the risk of co-morbidities.

**Aim:** To determine mean weight loss and BMI reduction for male patients following 8 weeks on the LighterLife Total for Men VLCD in 2009.

**Method:** Following screening suitability, patients started VLCD and were weighed and had ketone levels checked weekly by their LighterLife weight-management counsellors. This study reports on 950 men with BMI $\geq$ 30 who completed 8 weeks on the LighterLife Total for Men VLCD programme from January–September 2009.

**Results:** A mean weight loss of 19.5 kg (3st 11lb) following 8 weeks on the LighterLife Total for Men VLCD and a mean BMI reduction of 6.1 were observed in male patients.

Mean start weight	123.2 kg (19st 5lb)
Mean start BMI	38.6
Mean weight loss at 8 weeks	19.5 kg (3st 11lb)
Mean % weight loss	15.8%
Mean BMI reduction	6.1

**Conclusion:** Obese men completing 8 weeks on the LighterLife Total for Men VLCD achieved a mean loss of 19.5 kg (3st 11lb), which is a mean BMI reduction of 6.1 and in excess of 15% of their body weight. This may improve health outcomes by reducing the risk of weight-related co-morbidities.

T3:PO.72

### Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format

Milsom V<sup>1</sup>, Malcolm R<sup>1</sup>, Cronan G<sup>1</sup>, Pechon S<sup>1</sup>, Miller-Kovach K<sup>2</sup>, Rost S<sup>2</sup>, O'Neil PM<sup>1</sup>

<sup>1</sup>Weight Management Center, Medical University of South Carolina, Charleston, SC, USA; <sup>2</sup>Weight Watchers International, New York, NY, USA

**Introduction:** Average loss of 5–10% of body weight often improves cardiovascular risk factors. This is usually shown after 6–12 months of exposure to weight loss medications and/or intensive dietary, behavioral and/or exercise instruction. We assessed changes in risk factors after 12 weeks in a weight loss trial featuring a commercial format with limited dietary and exercise instruction.

**Methods:** Subjects (132 adults; BMI = 27–35) were randomized to 1 of 2 methods of counting food intake with weekly group meetings using a commercial weight loss program. Lipids, blood glucose, blood pressure and waist circumference were assessed at baseline and Week 12.

**Results:** One hundred and twelve subjects (100F,12M) completed final assessments. With no weight loss differences between conditions, analyses used the combined sample. Mean weight loss was 3.74 kg (SD = 3.16) and 4.37% of baseline weight (SD = 3.71). Significant improvements ( $P < .05$ ) were seen on triglycerides, total cholesterol and LDL cholesterol. There were trends ( $P < .10$ ) toward reductions in fasting glucose, systolic blood pressure, and HDL cholesterol. Among subjects with baseline values of the risk factor beyond recommended cut points, significant ( $P < .05$ ) reductions were seen on triglycerides ( $n = 22$ ), total cholesterol ( $n = 41$ ), LDL cholesterol ( $n = 77$ ), glucose ( $n = 8$ ), systolic and diastolic blood pressure ( $n = 14$ ), and waist circumference ( $n = 88$ ), and a trend ( $P < .10$ ) toward an increase in HDL ( $n = 57$ ).

**Conclusion:** With modest weight loss over 12 weeks using a commercial format with limited diet instruction, improvements were seen in a number of risk factors, particularly among subjects with initially higher-risk values. The duration of these effects remains to be determined.

**Conflict of interest:** Research support (RM, GC, SP, PO) and employment (KK, SR) by Weight Watchers International.

**Funding:** This study was supported by a grant from Weight Watchers International.